0
Il n'y a pas de produit dans le panier !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Accueil > Claudin-18.2

Claudin-18.2

Brief Information

Name:Claudin-18 splice variant 2
Target Synonym:UNQ778/PRO1572,CLDN18,Claudin 18,Surfactant Associated Protein J,Surfactant, Pulmonary Associated Protein J,Surfactant Associated 5,Claudin-18,SFTA5,SFTPJ,Claudin 18.2,CLDN18.2
Number of Launched Drugs:1
Number of Drugs in Clinical Trials:61
Lastest Research Phase:Approved

Antibody Licensing

Project Name Project Stage Molecule Type Host Species Therapeutic Area Indications
CLDN18.2 CAR-T - 01 PhaseI Solid Tumor Advanced refractory gastrointestinal tumors
CLDN18.2 VHH - 01 Lead Solid Tumor Gastric Cancer,Pancreatic cancer

Licensing

Project Name Modality Therapeutic Area Indications Stage Right Available
Claudin18.2 mAb Monospecific antibody Oncology/Cancer Gastric cancer Phase I Global
Claudin18.2×CD8+ T bsAb Bispecific antibody Oncology/Cancer Gastric cancer,Pancreatic cancer,Oophoroma IND Global

Product ListCompare or Buy

ACRO Quality

Part of Bioactivity data

CL2-HF218-Cell-based assay
 Claudin-18.2 FACS

2e5 of Anti-Claudin-18.2 CAR-293 cells were stained with 100 μL of 3 μg/mL of Fluorescent Human Claudin-18.2 Full Length Protein-VLP (Cat. No.CL2-HF218) and negative control protein respectively, FITC signals was used to evaluate the binding activity (QC tested).

CHEK-ATP033-Cell-based assay
 Claudin-18.2 FACS

FACS assay shows that Anti-Claudin-18.2 antibody can bind to HEK293/Human Claudin-18.2 Stable Cell Line. HEK293/Human Claudin-18.2 stable cells was red line, Negative control HEK293 cells was grey line (QC tested).

CL2-H5586-SPR
 Claudin-18.2 SPR

Monoclonal Anti-Chimeric Claudin-18.2 Antibody, Human IgG1 captured on Protein A Chip can bind Human / Cynomolgus Claudin-18.2, His,Twin-Strep Tag (Cat. No. CL2-H5586) with an affinity constant of 12.6 nM as determined in SPR assay (Biacore 8K) (Routinely tested).

CL2-M5585-SPR
 Claudin-18.2 SPR

Claudin-18.1 Monoclonal Antibody captured on CM5 chip via anti-mouse antibodies surface can bind Mouse Claudin-18.2, His,Twin-Strep Tag (Cat. No. CL2-M5585) with an affinity constant of 13 nM as determined in a SPR assay (in presence of DDM and CHS) (Biacore 8K) (Routinely tested).

Synonym Name

Claudin-18.2,CLDN18,Claudin-18

Background

Claudins (CLDNs) are a family of proteins that form tight junctions and maintain the polarity of epithelial and endothelial cells. CLDN18 is specifically expressed in the stomach and lung. Of the two CLDN18 isoform transcripts produced by alternative splicing, CLDN18.2 is a highly selective gastric lineage marker that determines the gastric phenotype in a neoplastic condition, whereas CLDN18.1 is lung specific. CLDN18.2 is a highly selective gastric lineage antigen expressed exclusively on short-lived differentiated gastric epithelial cells where it has only limited accessibility to antibody drugs.14,15 CLDN18.2 is maintained during the course of malignant transformation and thus frequently displayed on the surface of human gastric cancer cells.

Clinical and Translational Updates

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Zolbetuximab GC-182; iMAB-362; IMAB-362 Approved Ganymed Vyloy, VYLOY Japan Stomach Neoplasms Astellas Pharma Inc 2024-03-26 Solid tumours; Lymphangioma, Cystic; Esophageal Neoplasms; Stomach Neoplasms; Pain; Gastrointestinal Diseases; Pancreatic Neoplasms; Adenocarcinoma Details
Zolbetuximab GC-182; iMAB-362; IMAB-362 Approved Ganymed Vyloy, VYLOY Japan Stomach Neoplasms Astellas Pharma Inc 2024-03-26 Solid tumours; Lymphangioma, Cystic; Esophageal Neoplasms; Stomach Neoplasms; Pain; Gastrointestinal Diseases; Pancreatic Neoplasms; Adenocarcinoma Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Osemitamab MSB-018; TST-001 Phase 3 Clinical Mabspace Biomedicine (Suzhou) Co Ltd, HJB (Hangzhou) Co Ltd Biliary Tract Neoplasms; Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Neoplasms; Pancreatic Neoplasms; Digestive System Neoplasms; Lung Neoplasms; Gallbladder Neoplasms; Gastrointestinal Neoplasms Details
IBI-343 IBI-343 Phase 3 Clinical Innovent Biologics(Suzhou) Co Ltd Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Neoplasms Details
LM-302 TPX-4589; LM-302 Phase 3 Clinical Eli Lilly Trading (Shanghai) Co Ltd Solid tumours; Stomach Neoplasms; Esophageal Neoplasms; Neoplasms; Pancreatic Neoplasms; Gastrointestinal Neoplasms Details
SHR-A-1904 SHR-A-1904; SHR-A1904 Phase 3 Clinical Shanghai Hengrui Pharmaceutical Co Ltd Solid tumours; Pancreatic Neoplasms Details
M-108 M108; M-108 Phase 3 Clinical FutureGen Biopharm (Beijing) Co Ltd Solid tumours; Esophageal Neoplasms; Stomach Neoplasms Details
CMG-901 CMG-901; CMG901; AZD-0901; AZD0901 Phase 3 Clinical Keymed Biosciences Co Ltd Solid tumours; Stomach Neoplasms; Esophageal Neoplasms; Pancreatic Neoplasms; Digestive System Neoplasms; Gastrointestinal Neoplasms; Adenocarcinoma Details
ASKB-589 ASKB-589 Phase 3 Clinical Jiangsu Aosaikang Pharmaceutical Co Ltd, AskGene Pharma Inc Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Pancreatic Neoplasms; Adenocarcinoma Details
KD-182 KD-182 Phase 2 Clinical Nanjing Kaedi Biotechnology Co Ltd Stomach Neoplasms; Carcinoma, Pancreatic Ductal Details
Recombinant humanized anti-Claudin 18.2 monoclonal antibody (CARsgen) AB-011 Phase 2 Clinical Kaixing Life Technology (Shanghai) Co Ltd, Carsgen Biomedicine (Shanghai) Co Ltd Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Pancreatic Neoplasms Details
CLDN18.2-TAC T cells Therapy CLDN-18.2-TAC T cells; CLDN18.2-TAC T cells Phase 2 Clinical Triumvira Immunologics Inc Solid tumours; Stomach Neoplasms; Neoplasm Metastasis Details
HBM-7022 HBM-7022; AZD-5863 Phase 2 Clinical Harbour Biomed Esophageal Neoplasms; Stomach Neoplasms; Pancreatic Neoplasms; Neoplasms; Digestive System Neoplasms; Esophageal adenocarcinoma; Carcinoma, Pancreatic Ductal; Gastrointestinal Neoplasms Details
XNW-27011 XNW-27011 Phase 2 Clinical Suzhou Sinovent Pharmaceuticals Co Ltd Solid tumours Details
IMC-002(Suzhou Immunofoco) IMC-002 Phase 2 Clinical Suzhou Immunofoco Biotechnology Co Ltd Ovarian Neoplasms; Esophageal Neoplasms; Stomach Neoplasms; Pancreatic Neoplasms; Digestive System Neoplasms; Adenocarcinoma Details
PM-1032 PM1032; PM-1032 Phase 2 Clinical Biotheus Inc, Shanghai Genechem Co Ltd Neoplasms Details
PT-886 PT-886; PT886 Phase 2 Clinical Phanes Therapeutics Inc Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Pancreatic Neoplasms; Carcinoma, Pancreatic Ductal Details
ATG-022 ATG-022 Phase 2 Clinical Antengene Corporation Co Ltd Solid tumours; Stomach Neoplasms; Neoplasms; Neoplasm Metastasis Details
QLS-31905 QLS-31905 Phase 2 Clinical Qilu Pharmaceutical Co Ltd Solid tumours; Neoplasms Details
SOT-102 SOT-102; SOT102; SO-N102 Phase 2 Clinical Sotio Biotech AG Stomach Neoplasms; Esophageal Neoplasms; Pancreatic Neoplasms; Digestive System Neoplasms; Gastrointestinal Neoplasms Details
Q-1802 Q-1802 Phase 2 Clinical Qiyu Biotechnology (Shanghai) Co Ltd Solid tumours; Esophageal Neoplasms; Gastrointestinal Neoplasms Details
Recombinant humanized monoclonal antibody MIL93(Mabworks) MIL-93 Phase 2 Clinical Beijing Mabworks Biotech Co Ltd Solid tumours; Neoplasms Details
RC-118 RC-118; YH005 ADC Phase 2 Clinical RemeGen Co Ltd, Biocytogen Pharmaceuticals (Beijing) Co Ltd Solid tumours; Neoplasm Metastasis Details
Satricabtagene autoleucel CT041; CT-041 Phase 2 Clinical CARsgen Therapeutics Holdings Ltd Solid tumours; Stomach Neoplasms; Esophageal Neoplasms; Pancreatic Neoplasms; Adenocarcinoma Details
SPX-101 (Sparx Therapeutics) KY-71113; SX-001; KY71113; SPX-101 Phase 1 Clinical Sparx Therapeutics Inc, Kpc Pharmaceuticals Inc Solid tumours; Stomach Neoplasms Details
IM-92 IM-92 Phase 1 Clinical Beijing Immunochina Medical Science & Technology Co Ltd Esophageal Neoplasms; Stomach Neoplasms; Pancreatic Neoplasms Details
KD-496 KD-496(4th); KD-496 Phase 1 Clinical Nanjing Kaedi Biotechnology Co Ltd Solid tumours; Stomach Neoplasms; Neoplasms; Pancreatic Neoplasms Details
Gresonitamab AMG-910 Phase 1 Clinical Amgen Inc Stomach Neoplasms; Esophageal Neoplasms; Adenocarcinoma Details
AZD-6422 AZD6422; AZD-6422 Phase 1 Clinical Astrazeneca Plc Gastrointestinal Neoplasms Details
68Ga-PMD22(Peking Union Medical College Hospital) Phase 1 Clinical Peking Union Medical College Hospital Gastrointestinal Neoplasms Details
AK-132 AK132; AK-132 Phase 1 Clinical Zhongshan Akeso Biopharma Co Ltd Solid tumours; Neoplasms Details
TQB-2103 TQB2103; TQB-2103 Phase 1 Clinical Nanjing Shunxin Pharmaceuticals Co Ltd Of Chiatai Tianqing Pharmaceutical Group Neoplasms Details
BIO-008 BIO-008 Phase 1 Clinical Shijiazhuang Yiling Pharmaceutical Co Ltd Solid tumours Details
BA-1301 BA-1301; BA1301 Phase 1 Clinical Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Pancreatic Neoplasms Details
LB-1904 LB-1904 Phase 1 Clinical Stomach Neoplasms Details
CT-048 CT-048; KJ-C1807; KJ-C-1807 Phase 1 Clinical Carsgen Biomedicine (Shanghai) Co Ltd Esophageal Neoplasms; Stomach Neoplasms; Pancreatic Neoplasms; Adenocarcinoma Details
ASP-2138 ASP-2138 Phase 1 Clinical Astellas Pharma Global Development Inc, Xencor Inc Stomach Neoplasms; Esophageal Neoplasms; Pancreatic Neoplasms Details
LB-4330 Bis-2; LB-4330 Phase 1 Clinical L&L Biopharma Co Ltd Solid tumours Details
HEC-016 HEC-016 Phase 1 Clinical People Hospital Of Luohu,Shenzhen Esophageal Neoplasms; Stomach Neoplasms; Pancreatic Neoplasms Details
PM-3023 PM-3023 Phase 1 Clinical Biotheus Inc Solid tumours Details
RD-07 RD-07 Phase 1 Clinical Peking University Solid tumours Details
JS-107 JS-107; JS107 Phase 1 Clinical Shanghai Junshi Biosciences Co Ltd Solid tumours; Pancreatic Neoplasms Details
TORL-2-307-ADC TORL-2-307-ADC Phase 1 Clinical Torl Biotherapeutics LLC Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Pancreatic Neoplasms; Adenocarcinoma Details
BC-008 BC-008 Phase 1 Clinical Dragonboat Biopharmaceutical Solid tumours; Neoplasms Details
BC-007 (Dragonboat Biopharmaceutical) BC-007 Phase 1 Clinical Dragonboat Biopharmaceutical Solid tumours; Neoplasms Details
DR-30303 DR30303 Phase 1 Clinical Zhejiang Doer Biologics Corp Solid tumours Details
SG-1906 SG-1906; SG1906 Phase 1 Clinical Hangzhou Sumgen Biotechnology Co Ltd Solid tumours; Neoplasms Details
SKB-315 SKB-315; SKB315 Phase 1 Clinical Sichuan Kelun-Biotech Biopharmaceutical Co Ltd Solid tumours Details
BA-1105 BA-1105; BA1105 Phase 1 Clinical Solid tumours; Stomach Neoplasms; Esophageal Neoplasms; Pancreatic Neoplasms Details
LY-011(Shanghai Longyao) LY-011 Phase 1 Clinical Shanghai Longyao Biological Technology Co Ltd Stomach Neoplasms; Pancreatic Neoplasms Details
IBI-389 IBI-389 Phase 1 Clinical Innovent Biologics(Suzhou) Co Ltd Solid tumours; Neoplasms Details
NBL-015 NBL-015 Phase 1 Clinical Shanghai Xinshi Biological Medicine Co Ltd Solid tumours; Stomach Neoplasms; Pancreatic Neoplasms Details
IBI-360 IBI-360 Phase 1 Clinical Innovent Biologics(Suzhou) Co Ltd Solid tumours; Neoplasms Details
SYSA-1801 SYSA-1801; SYSA1801; CPO-102; EO-3021 Phase 1 Clinical Jushi Biopharmaceutical Co Ltd Solid tumours; Stomach Neoplasms; Esophageal Neoplasms; Pancreatic Neoplasms; Neoplasms; Digestive System Neoplasms; Gastrointestinal Neoplasms Details
Givastomig TJ-CD4B; ABL-111; TJ-CLDN4B; TJ-033721; TJ-CD4B/ABL111 Phase 1 Clinical I-Mab Biopharma Co Ltd Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Neoplasms; Esophageal adenocarcinoma; Neoplasm Metastasis Details
QL-1779 QL-1779; QL1779 Phase 1 Clinical Qilu Pharmaceutical Co Ltd Solid tumours Details
LM-102 LM-102 Phase 1 Clinical LaNova Medicines Ltd Solid tumours; Biliary Tract Neoplasms; Stomach Neoplasms; Esophageal Neoplasms; Pancreatic Neoplasms Details
HBM-1029 HBM-1029; HBM1029 Phase 1 Clinical Harbour Biomed Solid tumours; Stomach Neoplasms; Esophageal Neoplasms Details
LCAR-C18S CAR-T cell therapy LB-1908; LCAR-C18S; LCAR-C-18-S Phase 1 Clinical Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Pancreatic Neoplasms; Digestive System Neoplasms; Gastrointestinal Neoplasms Details
CLDN18.2 UCAR-T cell therapy CLDN18.2 UCAR-T Clinical Zhongshan City People'S Hospital, T-Maximum Pharmaceutical (Suzhou) Co Ltd Stomach Neoplasms Details
124I-18B10 124-I-18-B-10; 124I-18B10 Clinical Transcenta Holding Ltd, Beijing Cancer Hospital Gastrointestinal Neoplasms Details
89Zr-NY005 89Zr-NY005 Clinical Wuxi No 4 People'S Hospital Solid tumours Details
IBI-345 IBI-345 Innovent Biologics(Suzhou) Co Ltd Details
Osemitamab MSB-018; TST-001 Phase 3 Clinical Mabspace Biomedicine (Suzhou) Co Ltd, HJB (Hangzhou) Co Ltd Biliary Tract Neoplasms; Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Neoplasms; Pancreatic Neoplasms; Digestive System Neoplasms; Lung Neoplasms; Gallbladder Neoplasms; Gastrointestinal Neoplasms Details
IBI-343 IBI-343 Phase 3 Clinical Innovent Biologics(Suzhou) Co Ltd Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Neoplasms Details
LM-302 TPX-4589; LM-302 Phase 3 Clinical Eli Lilly Trading (Shanghai) Co Ltd Solid tumours; Stomach Neoplasms; Esophageal Neoplasms; Neoplasms; Pancreatic Neoplasms; Gastrointestinal Neoplasms Details
SHR-A-1904 SHR-A-1904; SHR-A1904 Phase 3 Clinical Shanghai Hengrui Pharmaceutical Co Ltd Solid tumours; Pancreatic Neoplasms Details
M-108 M108; M-108 Phase 3 Clinical FutureGen Biopharm (Beijing) Co Ltd Solid tumours; Esophageal Neoplasms; Stomach Neoplasms Details
CMG-901 CMG-901; CMG901; AZD-0901; AZD0901 Phase 3 Clinical Keymed Biosciences Co Ltd Solid tumours; Stomach Neoplasms; Esophageal Neoplasms; Pancreatic Neoplasms; Digestive System Neoplasms; Gastrointestinal Neoplasms; Adenocarcinoma Details
ASKB-589 ASKB-589 Phase 3 Clinical Jiangsu Aosaikang Pharmaceutical Co Ltd, AskGene Pharma Inc Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Pancreatic Neoplasms; Adenocarcinoma Details
KD-182 KD-182 Phase 2 Clinical Nanjing Kaedi Biotechnology Co Ltd Stomach Neoplasms; Carcinoma, Pancreatic Ductal Details
Recombinant humanized anti-Claudin 18.2 monoclonal antibody (CARsgen) AB-011 Phase 2 Clinical Kaixing Life Technology (Shanghai) Co Ltd, Carsgen Biomedicine (Shanghai) Co Ltd Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Pancreatic Neoplasms Details
CLDN18.2-TAC T cells Therapy CLDN-18.2-TAC T cells; CLDN18.2-TAC T cells Phase 2 Clinical Triumvira Immunologics Inc Solid tumours; Stomach Neoplasms; Neoplasm Metastasis Details
HBM-7022 HBM-7022; AZD-5863 Phase 2 Clinical Harbour Biomed Esophageal Neoplasms; Stomach Neoplasms; Pancreatic Neoplasms; Neoplasms; Digestive System Neoplasms; Esophageal adenocarcinoma; Carcinoma, Pancreatic Ductal; Gastrointestinal Neoplasms Details
XNW-27011 XNW-27011 Phase 2 Clinical Suzhou Sinovent Pharmaceuticals Co Ltd Solid tumours Details
IMC-002(Suzhou Immunofoco) IMC-002 Phase 2 Clinical Suzhou Immunofoco Biotechnology Co Ltd Ovarian Neoplasms; Esophageal Neoplasms; Stomach Neoplasms; Pancreatic Neoplasms; Digestive System Neoplasms; Adenocarcinoma Details
PM-1032 PM1032; PM-1032 Phase 2 Clinical Biotheus Inc, Shanghai Genechem Co Ltd Neoplasms Details
PT-886 PT-886; PT886 Phase 2 Clinical Phanes Therapeutics Inc Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Pancreatic Neoplasms; Carcinoma, Pancreatic Ductal Details
ATG-022 ATG-022 Phase 2 Clinical Antengene Corporation Co Ltd Solid tumours; Stomach Neoplasms; Neoplasms; Neoplasm Metastasis Details
QLS-31905 QLS-31905 Phase 2 Clinical Qilu Pharmaceutical Co Ltd Solid tumours; Neoplasms Details
SOT-102 SOT-102; SOT102; SO-N102 Phase 2 Clinical Sotio Biotech AG Stomach Neoplasms; Esophageal Neoplasms; Pancreatic Neoplasms; Digestive System Neoplasms; Gastrointestinal Neoplasms Details
Q-1802 Q-1802 Phase 2 Clinical Qiyu Biotechnology (Shanghai) Co Ltd Solid tumours; Esophageal Neoplasms; Gastrointestinal Neoplasms Details
Recombinant humanized monoclonal antibody MIL93(Mabworks) MIL-93 Phase 2 Clinical Beijing Mabworks Biotech Co Ltd Solid tumours; Neoplasms Details
RC-118 RC-118; YH005 ADC Phase 2 Clinical RemeGen Co Ltd, Biocytogen Pharmaceuticals (Beijing) Co Ltd Solid tumours; Neoplasm Metastasis Details
Satricabtagene autoleucel CT041; CT-041 Phase 2 Clinical CARsgen Therapeutics Holdings Ltd Solid tumours; Stomach Neoplasms; Esophageal Neoplasms; Pancreatic Neoplasms; Adenocarcinoma Details
SPX-101 (Sparx Therapeutics) KY-71113; SX-001; KY71113; SPX-101 Phase 1 Clinical Sparx Therapeutics Inc, Kpc Pharmaceuticals Inc Solid tumours; Stomach Neoplasms Details
IM-92 IM-92 Phase 1 Clinical Beijing Immunochina Medical Science & Technology Co Ltd Esophageal Neoplasms; Stomach Neoplasms; Pancreatic Neoplasms Details
KD-496 KD-496(4th); KD-496 Phase 1 Clinical Nanjing Kaedi Biotechnology Co Ltd Solid tumours; Stomach Neoplasms; Neoplasms; Pancreatic Neoplasms Details
Gresonitamab AMG-910 Phase 1 Clinical Amgen Inc Stomach Neoplasms; Esophageal Neoplasms; Adenocarcinoma Details
AZD-6422 AZD6422; AZD-6422 Phase 1 Clinical Astrazeneca Plc Gastrointestinal Neoplasms Details
68Ga-PMD22(Peking Union Medical College Hospital) Phase 1 Clinical Peking Union Medical College Hospital Gastrointestinal Neoplasms Details
AK-132 AK132; AK-132 Phase 1 Clinical Zhongshan Akeso Biopharma Co Ltd Solid tumours; Neoplasms Details
TQB-2103 TQB2103; TQB-2103 Phase 1 Clinical Nanjing Shunxin Pharmaceuticals Co Ltd Of Chiatai Tianqing Pharmaceutical Group Neoplasms Details
BIO-008 BIO-008 Phase 1 Clinical Shijiazhuang Yiling Pharmaceutical Co Ltd Solid tumours Details
BA-1301 BA-1301; BA1301 Phase 1 Clinical Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Pancreatic Neoplasms Details
LB-1904 LB-1904 Phase 1 Clinical Stomach Neoplasms Details
CT-048 CT-048; KJ-C1807; KJ-C-1807 Phase 1 Clinical Carsgen Biomedicine (Shanghai) Co Ltd Esophageal Neoplasms; Stomach Neoplasms; Pancreatic Neoplasms; Adenocarcinoma Details
ASP-2138 ASP-2138 Phase 1 Clinical Astellas Pharma Global Development Inc, Xencor Inc Stomach Neoplasms; Esophageal Neoplasms; Pancreatic Neoplasms Details
LB-4330 Bis-2; LB-4330 Phase 1 Clinical L&L Biopharma Co Ltd Solid tumours Details
HEC-016 HEC-016 Phase 1 Clinical People Hospital Of Luohu,Shenzhen Esophageal Neoplasms; Stomach Neoplasms; Pancreatic Neoplasms Details
PM-3023 PM-3023 Phase 1 Clinical Biotheus Inc Solid tumours Details
RD-07 RD-07 Phase 1 Clinical Peking University Solid tumours Details
JS-107 JS-107; JS107 Phase 1 Clinical Shanghai Junshi Biosciences Co Ltd Solid tumours; Pancreatic Neoplasms Details
TORL-2-307-ADC TORL-2-307-ADC Phase 1 Clinical Torl Biotherapeutics LLC Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Pancreatic Neoplasms; Adenocarcinoma Details
BC-008 BC-008 Phase 1 Clinical Dragonboat Biopharmaceutical Solid tumours; Neoplasms Details
BC-007 (Dragonboat Biopharmaceutical) BC-007 Phase 1 Clinical Dragonboat Biopharmaceutical Solid tumours; Neoplasms Details
DR-30303 DR30303 Phase 1 Clinical Zhejiang Doer Biologics Corp Solid tumours Details
SG-1906 SG-1906; SG1906 Phase 1 Clinical Hangzhou Sumgen Biotechnology Co Ltd Solid tumours; Neoplasms Details
SKB-315 SKB-315; SKB315 Phase 1 Clinical Sichuan Kelun-Biotech Biopharmaceutical Co Ltd Solid tumours Details
BA-1105 BA-1105; BA1105 Phase 1 Clinical Solid tumours; Stomach Neoplasms; Esophageal Neoplasms; Pancreatic Neoplasms Details
LY-011(Shanghai Longyao) LY-011 Phase 1 Clinical Shanghai Longyao Biological Technology Co Ltd Stomach Neoplasms; Pancreatic Neoplasms Details
IBI-389 IBI-389 Phase 1 Clinical Innovent Biologics(Suzhou) Co Ltd Solid tumours; Neoplasms Details
NBL-015 NBL-015 Phase 1 Clinical Shanghai Xinshi Biological Medicine Co Ltd Solid tumours; Stomach Neoplasms; Pancreatic Neoplasms Details
IBI-360 IBI-360 Phase 1 Clinical Innovent Biologics(Suzhou) Co Ltd Solid tumours; Neoplasms Details
SYSA-1801 SYSA-1801; SYSA1801; CPO-102; EO-3021 Phase 1 Clinical Jushi Biopharmaceutical Co Ltd Solid tumours; Stomach Neoplasms; Esophageal Neoplasms; Pancreatic Neoplasms; Neoplasms; Digestive System Neoplasms; Gastrointestinal Neoplasms Details
Givastomig TJ-CD4B; ABL-111; TJ-CLDN4B; TJ-033721; TJ-CD4B/ABL111 Phase 1 Clinical I-Mab Biopharma Co Ltd Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Neoplasms; Esophageal adenocarcinoma; Neoplasm Metastasis Details
QL-1779 QL-1779; QL1779 Phase 1 Clinical Qilu Pharmaceutical Co Ltd Solid tumours Details
LM-102 LM-102 Phase 1 Clinical LaNova Medicines Ltd Solid tumours; Biliary Tract Neoplasms; Stomach Neoplasms; Esophageal Neoplasms; Pancreatic Neoplasms Details
HBM-1029 HBM-1029; HBM1029 Phase 1 Clinical Harbour Biomed Solid tumours; Stomach Neoplasms; Esophageal Neoplasms Details
LCAR-C18S CAR-T cell therapy LB-1908; LCAR-C18S; LCAR-C-18-S Phase 1 Clinical Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Pancreatic Neoplasms; Digestive System Neoplasms; Gastrointestinal Neoplasms Details
CLDN18.2 UCAR-T cell therapy CLDN18.2 UCAR-T Clinical Zhongshan City People'S Hospital, T-Maximum Pharmaceutical (Suzhou) Co Ltd Stomach Neoplasms Details
124I-18B10 124-I-18-B-10; 124I-18B10 Clinical Transcenta Holding Ltd, Beijing Cancer Hospital Gastrointestinal Neoplasms Details
89Zr-NY005 89Zr-NY005 Clinical Wuxi No 4 People'S Hospital Solid tumours Details
IBI-345 IBI-345 Innovent Biologics(Suzhou) Co Ltd Details

This web search service is supported by Google Inc.

totop

Laisser un message